Secondary progression activity monitoring in MS despite an early highly active treatment the SPAM study.
Cohen M, Rollot F, Debouverie M, Zephir H, Vukusic S, De Seze J, Labauge P, Landes-Chateau C, Mondot L, Levraut M, Ruet A, Berger E, Laplaud D, Ciron J, Bourre B, Le Page E, Papeix C, Thouvenot E, Al Khedr A, Stankoff B, Pelletier J, Maillart E, Casez O, Moreau T, Defer G, Clavelou P, Cabre P, Moulin S, Neau JP, Zedet M, Hankiewicz K, Doghri I, Nasr HB, Pottier C, Magy L, Boulos DD, Heinzlef O, Camdessanche JP, Coustans M, Nifle C, Brassat D, Casey R, Lebrun-Frenay C; OFSEP and SFSEP study groups.
Cohen M, et al. Among authors: le page e.
Eur J Neurol. 2025 May;32(5):e16583. doi: 10.1111/ene.16583.
Eur J Neurol. 2025.
PMID: 40312884
Free PMC article.